Press Releases

Aug 09, 2022
U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry’s First Allogeneic CAR T Phase 2 Pivotal Trial Clearance to Cover ALPHA2 Protocol and Chemistry Manufacturing and Controls (CMC) for Use of ALLO-501A Manufactured from Cell
May 19, 2022
Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing Potential Than Cells Derived from Patients with Cancer Findings Underscore Potential of Allogeneic CAR T Products to Improve Patient Outcomes SOUTH SAN FRANCISCO, Calif.
May 04, 2022
Pivotal Phase 2 ALPHA2 Trial of ALLO-501A in R/R Large B Cell Lymphoma Planned to Commence Mid 2022 Using Product from Cell Forge 1 (CF1) CF1 is Projected to Support the Manufacture of ~20,000 Doses of AlloCAR T™ Products Annually at Scale Clinical Updates from the CD19 and BCMA Programs Planned
Apr 28, 2022
New Position Aimed at Attracting, Retaining, and Cultivating a Best-in-Class Workforce as Allogene Scales its Operations for its Next Stage of Growth SOUTH SAN FRANCISCO, Calif. , April 28, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company
Displaying 1 - 10 of 23
Print Page
Email Alerts
RSS Feeds
Investor Contacts